SlideShare una empresa de Scribd logo
1 de 37
Descargar para leer sin conexión
DR.M.ANEEQUE
aneeque86@gmail.com
Department of Anesthesiology SICU and
Pain Management
Civil Hospital Karachi
Coagulation is a major haemostatic
function responsible for prevention and
termination of bleeding following injury.
It is balanced by fibrinolytic system.
MECHANISM OF BLOOD
COAGULATION
The blood coagulation takes place in three
steps.
i. Formation of prothombin activator in
response to rupture or damage to the blood
vessels.
ii. Conversion of prothombin activator to
thombin.
iii. The thrombin act as an enzyme to convert
fibrinogen to fibrin thread that mesh
platelates, Blood cells and plasma to form the
clots.
Coagulation system is divided into two
pathways
Extrinsic Pathway:
Which begins after trauma to vascular
wall and surrounding tissue.
Intrinsic Pathway:
Which begins in blood itself
Coagulation cascade
Coagulation cascade
Coagulation cascade
FIBRINOLYSIS
If coagulation is continue and un controlled
then spontaneous clot formation results
pathological state
The process of fibrinolysis results
breakdown of clot.
In this tissue injury -> release of
plasminogen -> plasmin which bind to
fibrin and form fibrin degradation producet
Prothrombin time (PT)
Test of Extrinsive pathway
Measure Vitamin K dependent factor activity
(factor II, VII, IX and X)
Normal value 12-14 seconds
International normalize ratio (INR)
Standardized PT reporting
Normal value 0.8-1.2 seconds
Most sensitive to alteration in factor VII levels.
Prolonged decrease of normal factor VII activity.
ACTIVATED PARTIAL PROTHROMBIN
(APTT)
Test for intrinsic common pathway
Depends activity of all coagulation factor except
factor VII, XIII
Normal value 25-35 seconds
Prolonged only if coagulation factor reduced to
<30% of normal
ACTIVATED CLOTTING TIME (ACT)
Monitor heparin anti-coagulant in the
cardiac vascular surgery.
Normal value 90-120 seconds.
THROMBIN CLOTTING TIME (TCT)
1. Reflect abnormalities in fibrinogen ->
fibrin.
2. Prolonged by heparin, low fibrinogen
thrombin inhibitor.
BLEEDING TIME (BT)
Monitor platelet function
Non-specific indicator of platelet function.
Unreliable
No evidence as a predictor of risk of hemorrhage
Useful indicator of efficacy of anti-platelet therapy.
Insensitive to mild platelet defect.
Lab Test Component Measured Normal Value
Bleeding Time Platelet Function,
Vascular integrity
3-10 minutes
PT I, II, V, VII, IX & X 12-14 seconds
APTT I,II,V,VIII,IX,X,XI &XII
except VII & XIII
24-35 seconds
Thrombin Time I & II 12-20 seconds
COAGULATION DISORDER
Congenital Disorder:
Disorder of clotting may not present until
challenged by trauma, surgery in adult life.
Acquired Disorder:
Is due to lack of synthesis of coagulation
factor.
Increased loss due to DIC, Massive Blood
Loss.
A family history of hemophilia A, B sex linked
recessive, Von willbrand disease
In severe hemophilia A (factor VIII) bleeding occurs
spontaneously.
In mild hemophilia A (factor VIII) bleeding occurs
only after trauma.
Medical problem such as liver disease,
malabsorption (Vitamin K Deficiency) infection,
malignancy, DIC, auto-immune disease,
systemic lupus erythematous, rheumatoid
arthritis as well as medication aspirin, NSAIDS.
Disorder Platelet Count PT/INR APTT TT Fibrinogen Others
Hemophilia A Normal
Normal
Increase
Normal
Normal Decrease VIII
Hemophilia B
Normal Normal
Increase
Normal
Normal
Decrease IX
Vonwillebrand
disease
Normal Normal
Increase
Normal
Normal
Decrease VIII,
VWF, Increase
bleeding time
Liver Disease
Normal
Increase Increase
Normal
Normal Decrease V
Vitamin K
deficiency
Normal Increase
Increase
Normal
Normal
Decrease II,
VII, IX & X
Massive
Transfusion
Decrease
Increase
Increase
Normal Normal /
Decrease
Normal FDP
(Fibrinogen de-
gradation
product)
Heparin
Normal Normal
Increase
Increase
Normal
Increase ANT
Xa
Warfarin
Normal Increase
Increase
Normal
Normal
Decrease II,
VII, IX & X
Haemostatic Process
Effected
Class of Drug Specific Drug
Platelet plug formation Anti Platelet drug NSAID,Clopidogrel
Coagulation cascade IV anticoagulant
oral anticoagulant
Heparin
Warferin
Fibrinolysis Fibrinolytic agent Streptokinase , urokinase
DRUGS EFFECTING COAGULATION
Prostaglandin
synthesis
ADP binding
GPIIb/IIIa receptor
Antiplatelet drug targets
Aspirin
inhibits cyclo-oxygenase
 thromboxane A2 synthesis
inhibits both COX 1 and COX 2
irreversibly
Should stop 7 days prior to
surgery
Coagulation cascade
COX-1 vs COX-2 inhibitors
• GI ulceration
• Haemorrhage
• Bronchospasm
• Interstitial nephritis, papillary
necrosis, proteinuria, renal failure
• Reye’s syndrome in children
Adverse effects
Alternative to aspirin
First choice for aspirin intolerance
Clopidogrel
Block activation of platelets by
reducing ADP activation of Gp IIb /
IIIa receptor complex
Should stop 5 days prior to surgery
Heparin
Glycoaminoglycan containing a mixture of sulfated
muco-polysaccharides of various sizes
- Un-fractionated (5000-30000 Da)
- Low molecular weight (LMWH) (1000-10000
Da)
Heparin
- enhances the action of Antithrombin III (AT-III) (plasma
protease inhibitor) 1000 fold ↑ activity
- antithrombin III inhibits clotting factor proteases,
Thrombin (IIa), IXa, Xa, XIa and XIIa, by forming stable complexes
- heparin binds to AT-III and causes a conformational change
thereby activating AT-III
LMWH
- predominantly inhibit factor Xa
Mechanism of Action
Coagulation cascade
Increased bleeding
- antidote (protamine sulfate)
Heparin induced thrombocytopaenia
Osteoporosis with long term high-dose
administration 3-6mths
Inhibit aldosterone synthesis
Adverse effects
Unpredictable pharmacokinetics
Requires regular monitoring
Infusion
Higher incidence of HITs
Rebound ischaemia
Unfractionated heparin
Eg Enoxaparin; Tinzaparin
More predictable pharmacokinetics
Lower incidence of heparin-associated thrombocytopenia
Ease of administration s/c injection
No need for monitoring
Possible improvement in outcomes of acute coronary
syndromes
Low Mol Weight Heparins
Highly plasma protein bound
Metabolised by liver
Substrate of CYP450 enzymes
Excreted in urine and stool
Warfarin
Should stop 2-4 days prior to surgery
Block the Vitamin K-dependent glutamate carboxylation
of precursor clotting
factors II, VII, IX and X
Also inhibits Proteins C & S
8-12 hour delay in action because of T1/2 of clotting
factors in plasma
recovery needs synthesis of new clotting factors
action is reversed with vitamin K
Mechanism of action
Coagulation cascade
Bleeding
Contraindicated in pregnancy
- teratogenic effects, crosses placenta risk
foetal haemorrhage
Warfarin induced skin necrosis
- paradoxical local thrombosis
- increased in patients with protein C or S
deficiency
"Purple toes syndrome," cholesterol
microembolization
Hepatic dysfunction
Adverse effects
Derived from bacterial protein
Cleaves Plasminogen
Low fibrin specificity
Cheap
Streptokinase
Fibrinolytics
Intrinsic compound
Isolated from urine or renal cell
cultures
Cleaves plasminogen
Urokinase
Coagulation cascade

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Platelet disoders
Platelet disodersPlatelet disoders
Platelet disoders
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Coagulation Disorders
Coagulation DisordersCoagulation Disorders
Coagulation Disorders
 
Coagulation profile and its uses
Coagulation profile and its usesCoagulation profile and its uses
Coagulation profile and its uses
 
Fresh frozen plasma
Fresh frozen plasmaFresh frozen plasma
Fresh frozen plasma
 
Clotting factors
Clotting factorsClotting factors
Clotting factors
 
Fibrinolytic system
Fibrinolytic systemFibrinolytic system
Fibrinolytic system
 
Primary hemostasis
Primary hemostasisPrimary hemostasis
Primary hemostasis
 
CME-Cryoprecipitate.ppt22mar
CME-Cryoprecipitate.ppt22marCME-Cryoprecipitate.ppt22mar
CME-Cryoprecipitate.ppt22mar
 
Prothrombin time and aptt
Prothrombin time and apttProthrombin time and aptt
Prothrombin time and aptt
 
Coagulation profile
Coagulation profile Coagulation profile
Coagulation profile
 
Cardiac biomarkers - I
Cardiac biomarkers  - ICardiac biomarkers  - I
Cardiac biomarkers - I
 
Blood,blood products and blood transfusion
Blood,blood products and blood transfusionBlood,blood products and blood transfusion
Blood,blood products and blood transfusion
 
Coagulation tests
Coagulation testsCoagulation tests
Coagulation tests
 
Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
 
Prothrombin time
Prothrombin timeProthrombin time
Prothrombin time
 
Liver function tests and interpretation
Liver function tests and interpretation Liver function tests and interpretation
Liver function tests and interpretation
 
Mechanism of Blood Coagulation
Mechanism of Blood Coagulation Mechanism of Blood Coagulation
Mechanism of Blood Coagulation
 
Blood transfusion complications
Blood transfusion complicationsBlood transfusion complications
Blood transfusion complications
 
Platelets and Hemostasis.pptx
Platelets and Hemostasis.pptxPlatelets and Hemostasis.pptx
Platelets and Hemostasis.pptx
 

Destacado

Coagulation cascade
Coagulation cascadeCoagulation cascade
Coagulation cascadeniraj phoju
 
Pathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery DiseasePathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery DiseaseNetraranjn
 
Lecture 6 the cardiovascular system blood
Lecture 6 the cardiovascular system bloodLecture 6 the cardiovascular system blood
Lecture 6 the cardiovascular system bloodNada G.Youssef
 
BODY FLUIDS AND CIRCULATION
BODY FLUIDS AND CIRCULATIONBODY FLUIDS AND CIRCULATION
BODY FLUIDS AND CIRCULATIONJigyasa Dhuria
 
Body systems and homeostasis
Body systems and homeostasisBody systems and homeostasis
Body systems and homeostasisfarrellw
 
Fragile x syndrome
Fragile x syndrome Fragile x syndrome
Fragile x syndrome Nik Syamimi
 
Hamostasis and blood coagulation
Hamostasis and blood coagulationHamostasis and blood coagulation
Hamostasis and blood coagulationdrmcbansal
 

Destacado (10)

Coagulation cascade
Coagulation cascadeCoagulation cascade
Coagulation cascade
 
Pathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery DiseasePathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery Disease
 
Lecture 6 the cardiovascular system blood
Lecture 6 the cardiovascular system bloodLecture 6 the cardiovascular system blood
Lecture 6 the cardiovascular system blood
 
BODY FLUIDS AND CIRCULATION
BODY FLUIDS AND CIRCULATIONBODY FLUIDS AND CIRCULATION
BODY FLUIDS AND CIRCULATION
 
Body systems and homeostasis
Body systems and homeostasisBody systems and homeostasis
Body systems and homeostasis
 
Coagulation cascade
Coagulation cascadeCoagulation cascade
Coagulation cascade
 
Blood Physiology - Ppt
Blood Physiology - PptBlood Physiology - Ppt
Blood Physiology - Ppt
 
Fragile x syndrome
Fragile x syndrome Fragile x syndrome
Fragile x syndrome
 
Blood coagulation
Blood coagulationBlood coagulation
Blood coagulation
 
Hamostasis and blood coagulation
Hamostasis and blood coagulationHamostasis and blood coagulation
Hamostasis and blood coagulation
 

Similar a Coagulation cascade

Similar a Coagulation cascade (20)

Hemorrhagic Syndromes
Hemorrhagic SyndromesHemorrhagic Syndromes
Hemorrhagic Syndromes
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Hemostasis Surgury 2
Hemostasis Surgury 2Hemostasis Surgury 2
Hemostasis Surgury 2
 
02a Surgical hemostasis
02a Surgical hemostasis02a Surgical hemostasis
02a Surgical hemostasis
 
Hemostasis
HemostasisHemostasis
Hemostasis
 
Itp
ItpItp
Itp
 
Heamostasis
HeamostasisHeamostasis
Heamostasis
 
Coagulation dirorder 2021
Coagulation dirorder 2021Coagulation dirorder 2021
Coagulation dirorder 2021
 
Seminar on hemostatsis
Seminar on hemostatsisSeminar on hemostatsis
Seminar on hemostatsis
 
An approach to a patient with Thrombocytopenia
An approach to a patient with ThrombocytopeniaAn approach to a patient with Thrombocytopenia
An approach to a patient with Thrombocytopenia
 
4. hemostasis, bleeding & BT.pptx
4. hemostasis, bleeding & BT.pptx4. hemostasis, bleeding & BT.pptx
4. hemostasis, bleeding & BT.pptx
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Snake Bite
Snake BiteSnake Bite
Snake Bite
 
Hemostatsis & blood transfusion
Hemostatsis & blood transfusionHemostatsis & blood transfusion
Hemostatsis & blood transfusion
 
5. bleeding disorder
5. bleeding disorder5. bleeding disorder
5. bleeding disorder
 
GIẢM TIỂU CẦU - HỘI CHỨNG HELLP
GIẢM TIỂU CẦU - HỘI CHỨNG HELLPGIẢM TIỂU CẦU - HỘI CHỨNG HELLP
GIẢM TIỂU CẦU - HỘI CHỨNG HELLP
 
Coagulopathy
CoagulopathyCoagulopathy
Coagulopathy
 
Antiplatelet new and anti coagulants : Dr Rahul Kunkulol's Power Point Prese...
Antiplatelet new  and anti coagulants : Dr Rahul Kunkulol's Power Point Prese...Antiplatelet new  and anti coagulants : Dr Rahul Kunkulol's Power Point Prese...
Antiplatelet new and anti coagulants : Dr Rahul Kunkulol's Power Point Prese...
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
Thrombocytopenia
 
Medicine 5th year, 10th lecture (Dr. Sabir)
Medicine 5th year, 10th lecture (Dr. Sabir)Medicine 5th year, 10th lecture (Dr. Sabir)
Medicine 5th year, 10th lecture (Dr. Sabir)
 

Más de MUHAMMAD ANEEQUE KHAN

Más de MUHAMMAD ANEEQUE KHAN (7)

Electrolyte imbalance
Electrolyte imbalanceElectrolyte imbalance
Electrolyte imbalance
 
fentanyl or ketamine in EUS
fentanyl or ketamine in EUSfentanyl or ketamine in EUS
fentanyl or ketamine in EUS
 
Geriatric anesthesia
Geriatric anesthesiaGeriatric anesthesia
Geriatric anesthesia
 
JOURNAL CLUB Possible predictors related to the complications of propofol-bas...
JOURNAL CLUB Possible predictors related to the complications of propofol-bas...JOURNAL CLUB Possible predictors related to the complications of propofol-bas...
JOURNAL CLUB Possible predictors related to the complications of propofol-bas...
 
8 cm pillow journal club
8 cm pillow journal club8 cm pillow journal club
8 cm pillow journal club
 
journal club
journal clubjournal club
journal club
 
Pain anatomy and physiology
Pain anatomy and physiologyPain anatomy and physiology
Pain anatomy and physiology
 

Último

Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 

Último (20)

GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 

Coagulation cascade

  • 1. DR.M.ANEEQUE aneeque86@gmail.com Department of Anesthesiology SICU and Pain Management Civil Hospital Karachi
  • 2. Coagulation is a major haemostatic function responsible for prevention and termination of bleeding following injury. It is balanced by fibrinolytic system.
  • 3. MECHANISM OF BLOOD COAGULATION The blood coagulation takes place in three steps. i. Formation of prothombin activator in response to rupture or damage to the blood vessels. ii. Conversion of prothombin activator to thombin. iii. The thrombin act as an enzyme to convert fibrinogen to fibrin thread that mesh platelates, Blood cells and plasma to form the clots.
  • 4. Coagulation system is divided into two pathways Extrinsic Pathway: Which begins after trauma to vascular wall and surrounding tissue. Intrinsic Pathway: Which begins in blood itself
  • 8. FIBRINOLYSIS If coagulation is continue and un controlled then spontaneous clot formation results pathological state The process of fibrinolysis results breakdown of clot. In this tissue injury -> release of plasminogen -> plasmin which bind to fibrin and form fibrin degradation producet
  • 9. Prothrombin time (PT) Test of Extrinsive pathway Measure Vitamin K dependent factor activity (factor II, VII, IX and X) Normal value 12-14 seconds International normalize ratio (INR) Standardized PT reporting Normal value 0.8-1.2 seconds Most sensitive to alteration in factor VII levels. Prolonged decrease of normal factor VII activity.
  • 10. ACTIVATED PARTIAL PROTHROMBIN (APTT) Test for intrinsic common pathway Depends activity of all coagulation factor except factor VII, XIII Normal value 25-35 seconds Prolonged only if coagulation factor reduced to <30% of normal
  • 11. ACTIVATED CLOTTING TIME (ACT) Monitor heparin anti-coagulant in the cardiac vascular surgery. Normal value 90-120 seconds.
  • 12. THROMBIN CLOTTING TIME (TCT) 1. Reflect abnormalities in fibrinogen -> fibrin. 2. Prolonged by heparin, low fibrinogen thrombin inhibitor.
  • 13. BLEEDING TIME (BT) Monitor platelet function Non-specific indicator of platelet function. Unreliable No evidence as a predictor of risk of hemorrhage Useful indicator of efficacy of anti-platelet therapy. Insensitive to mild platelet defect.
  • 14. Lab Test Component Measured Normal Value Bleeding Time Platelet Function, Vascular integrity 3-10 minutes PT I, II, V, VII, IX & X 12-14 seconds APTT I,II,V,VIII,IX,X,XI &XII except VII & XIII 24-35 seconds Thrombin Time I & II 12-20 seconds
  • 15. COAGULATION DISORDER Congenital Disorder: Disorder of clotting may not present until challenged by trauma, surgery in adult life. Acquired Disorder: Is due to lack of synthesis of coagulation factor. Increased loss due to DIC, Massive Blood Loss. A family history of hemophilia A, B sex linked recessive, Von willbrand disease
  • 16. In severe hemophilia A (factor VIII) bleeding occurs spontaneously. In mild hemophilia A (factor VIII) bleeding occurs only after trauma. Medical problem such as liver disease, malabsorption (Vitamin K Deficiency) infection, malignancy, DIC, auto-immune disease, systemic lupus erythematous, rheumatoid arthritis as well as medication aspirin, NSAIDS.
  • 17. Disorder Platelet Count PT/INR APTT TT Fibrinogen Others Hemophilia A Normal Normal Increase Normal Normal Decrease VIII Hemophilia B Normal Normal Increase Normal Normal Decrease IX Vonwillebrand disease Normal Normal Increase Normal Normal Decrease VIII, VWF, Increase bleeding time Liver Disease Normal Increase Increase Normal Normal Decrease V Vitamin K deficiency Normal Increase Increase Normal Normal Decrease II, VII, IX & X Massive Transfusion Decrease Increase Increase Normal Normal / Decrease Normal FDP (Fibrinogen de- gradation product) Heparin Normal Normal Increase Increase Normal Increase ANT Xa Warfarin Normal Increase Increase Normal Normal Decrease II, VII, IX & X
  • 18. Haemostatic Process Effected Class of Drug Specific Drug Platelet plug formation Anti Platelet drug NSAID,Clopidogrel Coagulation cascade IV anticoagulant oral anticoagulant Heparin Warferin Fibrinolysis Fibrinolytic agent Streptokinase , urokinase DRUGS EFFECTING COAGULATION
  • 20. Aspirin inhibits cyclo-oxygenase  thromboxane A2 synthesis inhibits both COX 1 and COX 2 irreversibly Should stop 7 days prior to surgery
  • 22. COX-1 vs COX-2 inhibitors
  • 23. • GI ulceration • Haemorrhage • Bronchospasm • Interstitial nephritis, papillary necrosis, proteinuria, renal failure • Reye’s syndrome in children Adverse effects
  • 24. Alternative to aspirin First choice for aspirin intolerance Clopidogrel Block activation of platelets by reducing ADP activation of Gp IIb / IIIa receptor complex Should stop 5 days prior to surgery
  • 25. Heparin Glycoaminoglycan containing a mixture of sulfated muco-polysaccharides of various sizes - Un-fractionated (5000-30000 Da) - Low molecular weight (LMWH) (1000-10000 Da)
  • 26. Heparin - enhances the action of Antithrombin III (AT-III) (plasma protease inhibitor) 1000 fold ↑ activity - antithrombin III inhibits clotting factor proteases, Thrombin (IIa), IXa, Xa, XIa and XIIa, by forming stable complexes - heparin binds to AT-III and causes a conformational change thereby activating AT-III LMWH - predominantly inhibit factor Xa Mechanism of Action
  • 28. Increased bleeding - antidote (protamine sulfate) Heparin induced thrombocytopaenia Osteoporosis with long term high-dose administration 3-6mths Inhibit aldosterone synthesis Adverse effects
  • 29. Unpredictable pharmacokinetics Requires regular monitoring Infusion Higher incidence of HITs Rebound ischaemia Unfractionated heparin
  • 30. Eg Enoxaparin; Tinzaparin More predictable pharmacokinetics Lower incidence of heparin-associated thrombocytopenia Ease of administration s/c injection No need for monitoring Possible improvement in outcomes of acute coronary syndromes Low Mol Weight Heparins
  • 31. Highly plasma protein bound Metabolised by liver Substrate of CYP450 enzymes Excreted in urine and stool Warfarin Should stop 2-4 days prior to surgery
  • 32. Block the Vitamin K-dependent glutamate carboxylation of precursor clotting factors II, VII, IX and X Also inhibits Proteins C & S 8-12 hour delay in action because of T1/2 of clotting factors in plasma recovery needs synthesis of new clotting factors action is reversed with vitamin K Mechanism of action
  • 34. Bleeding Contraindicated in pregnancy - teratogenic effects, crosses placenta risk foetal haemorrhage Warfarin induced skin necrosis - paradoxical local thrombosis - increased in patients with protein C or S deficiency "Purple toes syndrome," cholesterol microembolization Hepatic dysfunction Adverse effects
  • 35. Derived from bacterial protein Cleaves Plasminogen Low fibrin specificity Cheap Streptokinase Fibrinolytics
  • 36. Intrinsic compound Isolated from urine or renal cell cultures Cleaves plasminogen Urokinase